Quest Diagnostics Incorporated
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $992.0M | $871.0M | $854.0M | $946.0M | $2.00B | $1.43B | $858.0M | $736.0M |
| Depreciation & Amortization | $570.0M | $493.0M | $439.0M | $437.0M | $408.0M | $361.0M | $329.0M | $309.0M |
| Depreciation | $416.0M | $366.0M | $331.0M | $317.0M | $305.0M | $258.0M | $233.0M | $219.0M |
| Amortization | $154.0M | $127.0M | $108.0M | $120.0M | $103.0M | $103.0M | $96.0M | $90.0M |
| Stock-Based Compensation | $88.0M | $88.0M | $77.0M | $77.0M | $79.0M | $97.0M | $56.0M | $61.0M |
| Net Cash from Operating Activities | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.01B | $1.24B | $1.20B |
| Investing Activities | ||||||||
| Capital Expenditures | $527.0M | $425.0M | $408.0M | $404.0M | $403.0M | $418.0M | $400.0M | $383.0M |
| Business Acquisitions | $101.0M | $2.16B | $611.0M | $144.0M | $331.0M | $330.0M | $58.0M | $421.0M |
| Net Cash from Investing Activities | $-631.0M | $-2.55B | $-1.06B | $-543.0M | $21.0M | $-772.0M | $-411.0M | $-801.0M |
| Financing Activities | ||||||||
| Dividends Paid | $353.0M | $331.0M | $314.0M | $305.0M | $309.0M | $297.0M | $286.0M | $266.0M |
| Stock Repurchases | $450.0M | $151.0M | $275.0M | $1.41B | $2.20B | $325.0M | $353.0M | $322.0M |
| Net Cash from Financing Activities | $-1.39B | $1.08B | $160.0M | $-1.73B | $-2.54B | $-1.27B | $225.0M | $-401.0M |
| Net Change in Cash | $-129.0M | $-137.0M | $371.0M | $-557.0M | $-286.0M | — | — | — |
| Free Cash Flow | $1.36B | $909.0M | $864.0M | $1.31B | $1.83B | $1.59B | $843.0M | $817.0M |